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Comprehensive analysis of miRNA expression in T-cell subsets
of rheumatoid arthritis patients reveals defined signatures
of naive and memory Tregs
K Smigielska-Czepiel1,2, A van den Berg1, P Jellema1, RJ van der Lei1, J Bijzet3, J Kluiver1, AMH Boots2,3, E Brouwer2,3 and B-J Kroesen1,2,4
Disturbed expression of microRNAs (miRNAs) in regulatory T cells (Tregs) leads to development of autoimmunity in experimental
mouse models. However, the miRNA expression signature characterizing Tregs of autoimmune diseases, such as rheumatoid
arthritis (RA) has not been determined yet. In this study, we have used a microarray approach to comprehensively analyze miRNA
expression signatures of both naive Tregs (CD4þCD45RO-CD25þþ ) and memory Tregs (CD4þ CD45ROþCD25þþþ ), as well
as conventional naive (CD4þCD45ROCD25 ) and memory (CD4þ CD45ROþ CD25 ) T cells (Tconvs) derived from peripheral
blood of RA patients and matched healthy controls. Differential expression of selected miRNAs was validated by TaqMan-based
quantitative reverse transcription-PCR. We found a positive correlation between increased expression of miR-451 in T cells of RA
patients and disease activity score (DAS28), erythrocyte sedimentation rate levels and serum levels of interleukin-6. Moreover, we
found characteristic, disease- and treatment-independent, global miRNA expression signatures defining naive Tregs, memory Tregs,
naive Tconvs and memory Tconvs. The analysis allowed us to define miRNAs characteristic for a general naive phenotype (for
example, miR-92a) and a general memory phenotype (for example, miR-21, miR-155). Importantly, the analysis allowed us to define
miRNAs that are specifically expressed in both naive and memory Tregs, defining as such miRNA signature characterizing the Treg
phenotype (that is, miR-146a, miR-3162, miR-1202, miR-1246 and miR-4281).
Genes and Immunity (2014) 15, 115–125; doi:10.1038/gene.2013.69; published online 9 January 2014
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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease characterized
by chronic inflammation of synovial tissue that leads to damage of
cartilage and bone, resulting in irreversible joint destruction. A
number of genetic factors associated with RA suggest that deviant
regulation of T cells might have an important role in the
development and course of the disease.1–3 Moreover, despite
the large numbers of regulatory T cells (Tregs) present in the
synovial fluid of RA patients4–6 and despite the treatment, the
inflammatory state of the joint persists. This suggests a potential
functional defect in the Treg compartment or the resistance of
effector T cells to Treg-mediated suppression.7
Tregs maintain immune homeostasis through suppression of
excessive lymphocyte proliferation and cytokine production.8
Several studies have indicated that Tregs isolated from RA patients
are functionally compromised and fail to suppress production of
pro-inflammatory cytokines such as interleukin (IL)-17, interferon-g
and tumor necrosis factor (TNF)-a.9–11 Defective function of RA Tregs
has been associated with exposure to elevated levels of pro-
inflammatory cytokines in the synovial fluid of the inflamed joints.
TNF-a, by itself, was shown to affect the transcriptional profile of
protein-coding genes and the level of Foxp3 phosphorylation,
leading to decreased suppressive function of Tregs.12,13 In addition,
increased TNF-a levels detected in synovial fluid of RA patients
correlated positively with the deviant expression of microRNAs
(miRNAs) in T cells,14 indicating that the pro-inflammatory cytokines
affect T cells also at the post-transcriptional level.
MiRNAs are a class of small, 20–22 nucleotide long, noncoding
RNA species that regulate gene expression at the post-transcrip-
tional level. After loading into the RNA-induced silencing complex,
miRNAs prevent translation or promote degradation of target
mRNA by homologous binding to the 30-untranslated region.15
Thus, miRNAs regulate protein expression and allow intricate fine
tuning of cell biological processes. Over the last decade it has
become clear that miRNAs regulate the expression of genes in
fundamental biological processes related to development,16
proliferation17 and apoptosis18 as well as pathological processes
such as cancer and autoimmunity.19–21 The decisive impact of
miRNAs, on the functioning and lineage stability of T-cell subsets,
including Tregs, has been reported in a number of mouse
studies.21–23 Indeed, disruption of normal miRNA biogenesis in
Tregs leads to breakdown of tolerance and shifts in the lineage
specificity of Tregs in experimental model systems.24 A number of
studies have recently shown differential expression of specific
miRNAs in peripheral blood mononuclear cells, T-cells and tissues
of human inflammatory diseases, including systemic lupus
erythematosus and RA.14,25–28 However, the miRNA expression
of peripheral blood Tregs and conventional T cells (Tconvs) of RA
1Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 2Groningen Research Initiative on
Healthy Ageing and Immune Longevity (GRAIL), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 3Department of Rheumatology and
Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands and 4Department of Laboratory Medicine, University of
Groningen, University Medical Center Groningen, Groningen, The Netherlands. Correspondence: Dr B-J Kroesen, Department of Laboratory Medicine, University of Groningen,
University Medical Center Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands.
E-mail: b.j.kroesen@umcg.nl
Received 20 September 2013; revised 26 November 2013; accepted 3 December 2013; published online 9 January 2014
Genes and Immunity (2014) 15, 115–125
& 2014 Macmillan Publishers Limited All rights reserved 1466-4879/14
www.nature.com/gene
patients has not been reported yet. Miyara et al.29 have recently
showed that, similar to Tconvs, Tregs can be subclassified into
interrelated naive Tregs (that is, resting Tregs) and memory Tregs
(that is, activated Tregs), with both overlapping and distinct
phenotypic and functional characteristics. Importantly, such
classification allows a precise delineation of Treg subpopulations
and enables their efficient isolation.30
In this study, we set out to comprehensively analyze miRNA
expression signatures of four functionally relevant and distinct
CD4þ T-cell subsets (that is, naive Tregs, memory Tregs, naive
Tconvs and memory Tconvs) derived from RA patients, before and
after anti-TNF-a treatment, and from healthy donors. The global
T-cell subset-specific miRNA expression patterns were not altered
by either the disease state or the type of treatment received by RA
patients. However, the expression of miR-451 correlated positively
with the RA disease activity score (DAS28). Furthermore, the analysis
of the defined T-cell subsets provided characteristic expression
signatures of both naive and memory Treg and Tconv subsets.
RESULTS
The global T-cell subset-specific miRNA expression patterns are
not affected by RA or anti-inflammatory treatment
The miRNA signature of Tregs in RA was studied using a cohort of
27 RA patients fulfilling the 1987 ACR criteria for the classification
of RA and six healthy controls (HC). The characteristics of all
donors are summarized in Table 1. Possible confounding effects of
disease modifying anti-rheumatic drugs on T cells were accounted
for by including patients before and after the start of treatment
with disease modifying anti-rheumatic drugs. Patients were
further subdivided according to the type of treatment into two
groups, that is, patients treated with methotrexate (MTX) alone,
and patients treated with MTX and Adalimumab, an anti-TNF-a
monoclonal antibody. CD4þ Tregs and Tconvs were isolated
using the gating strategy devised by Miyara et al.,29 which allows
subclassification of T cells into naive Tregs (CD45RO
CD25þþ Foxp3þ ), memory Tregs (CD45ROþCD25þþþ
Foxp3þþ ), naive Tconvs (CD45RO CD25 Foxp3 ) and
memory Tconvs (CD45ROþCD25 Foxp3 ), as depicted in
Figure 1a. Differential expression of Foxp3 was assessed by
fluorescence-activated cell sorting staining (Figure 1b) and
confirmed in the sorted T-cell subsets by quantitative reverse
transcription (qRT)-PCR (Figure 1c). The percentage of naive and
memory Tregs, the expression level of Foxp3 transcript as well as
the percentage and numbers of monocytes, natural killer cells,
total T and B cells did not differ between HC and RA patient
groups (Supplementary Figures 1A and B, and data not shown).
The global miRNA expression patterns were determined in 24
subsets of six RA patients and in 8 subsets of two HC (Table 1,
array) using the Agilent Human miRNA Microarray (Agilent


















(mg per 2 weeks)
miRNA analysis type
Healthy controls
HC-2 F 44 ND ND ND ND — — — Array
HC-6b F 50 ND ND ND ND — — — Array
HC-1 M 45 ND ND ND ND — — — qRT–PCR validation
HC-3 F 52 ND ND ND ND — — — qRT–PCR validation
HC-5 F 53 ND ND ND ND — — — qRT–PCR validation
HC-7 F 48 ND ND ND ND — — — qRT–PCR validation
Newly diagnosed patients
RA new
RA-10 M 42 4.2 9 39 15 Yes — — Array
RA-27 M 50 2.9 15 4340 650 Yes — — Array
RA-4 M 46 5.4 67 91 21 Yes — — qRT–PCR validation
RA-14 F 42 6.0 30 468 71 Yes — — qRT–PCR validation
RA-33 F 29 4.5 51 4340 15 Yes — — qRT–PCR validation
RA-7 M 68 4.2 22 4340 78 Yes — — qRT–PCR 2
RA-12 F 43 3.8 11 43 196 Yes — — qRT–PCR 2
RA-32 F 51 5.4 37 328 69 Yes — — qRT–PCR 2
Treated patients
RA MTX
RA-15 M 45 1.3 3 4340 53 Yes 25 — Array
RA-22 F 56 5.2 15 4340 20 Yes 15 — Array
RA-1 F 60 5.3 20 0 0 No 15 — qRT–PCR validation
RA-9 F 80 4.0 33 0 0 Yes 20 — qRT–PCR validation
RA-21 F 54 2.8 38 107 71 Yes 15 — qRT–PCR validation
RA-26 M 67 3.4 11 0 16 Yes 15 — qRT–PCR validation
RA-13 M 50 3.9 6 0 0 Yes 25 — qRT–PCR 2
RA-16 F 30 7.8 70 3 436 Yes 25 — qRT–PCR 2
RA-18 M 50 3.7 3 1 13 Yes 25a — qRT–PCR 2
RA-20 F 30 5.9 27 3 436 Yes 25a — qRT–PCR 2
RA-23 F 48 3.1 13 34 31 Yes 25 — qRT–PCR 2
RA MTXþ anti-TNF-a
RA-8 F 41 2.7 5 15 224 Yes 15 40 Array
RA-28 F 30 2.7 18 4 29 Yes 25 40 Array
RA-2 F 62 2.7 12 42 33 Yes 15 40 qRT–PCR validation
RA-29 M 59 2.7 6 4340 590 Yes 10 40 qRT–PCR validation
RA-30 F 55 2.8 24 4340 593 No 20 40 qRT–PCR validation
RA-3 F 61 2.6 18 1 54 No 15 40b qRT–PCR 2
RA-11 M 60 2.5 16 41000 331 Yes 12.5 40 qRT–PCR 2
RA-31 F 51 1.8 13 4340 365 No — 40 qRT–PCR 2
Abbreviations: ACPA, anti-cyclic citrullinated peptide antibodies; DAS28, disease activity score; ESR, erythrocyte sedimentation rate; miRNA, microRNA;
MTX, methotrexate; ND, not determined; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumor necrosis factor. aPer 6 months. bPer month.
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Technologies, Santa Clara, CA, USA). One hundred and twenty-one
human miRNAs passed the detection criteria and were used in the
subsequent analysis. To determine whether or not the global
miRNA expression patterns were affected by the disease or the
type of treatment, we performed unsupervised hierarchical
clustering of all samples. Clustering separated the samples, with
one exception, into four phenotypic groups (naive Tconv, memory
Tconv, memory Treg and naive Treg), irrespective of the disease or
type of treatment, indicating that each T-cell subset is character-
ized by a very specific miRNA signature. No further biologically
meaningful clustering pattern was observed. This indicates that
the global miRNA expression patterns characterizing T-cell subsets
are not affected by the disease or the anti-inflammatory treatment
(Figures 2a and b).
Expression of miR-451 in T cells positively correlates with the
DAS28
To identify specific miRNAs that were differentially expressed as a
result of disease characteristics or treatment, we performed an
intergroup statistical analysis. From this analysis, miR-451 was
identified to be significantly higher expressed in patients treated
with MTX (RA MTX, fold difference X2, corrected P-value o0.05),
irrespective of the T-cell subset (Figure 3a). Surprisingly, qRT–PCR
analysis performed in a new cohort of 10 RA patients and 4 HC
(Table 1, qRT–PCR validation) identified miR-451 to be significantly
higher expressed in a group of newly diagnosed, disease
modifying anti-rheumatic drug-free RA patients (RA new;
Figure 3b). This discrepancy prompted us to investigate whether
the expression of miR-451 in T cells is related to the disease
characteristics of individual patients in the cohorts included in the
study. Indeed, analysis of 27 patients revealed that the expression
of miR-451 correlated positively with DAS28 and, more specifically,
with the erythrocyte sedimentation rate (ESR; Figures 3c and d).
Correlations with anti-cyclic citrullinated peptide antibodies,
rheumatoid factor level or age were not found (data not shown).
Both DAS28 score and ESR have been previously correlated with
the serum levels of pro-inflammatory cytokine IL-6.31 Moreover,
IL-6 has been shown to induce expression of miR-451 in dendritic
cells.32 To test whether an increased expression of miR-451 in
T cells could be related to an increased presence of IL-6, we
measured IL-6 levels in the sera of RA patients. Indeed, we found a
positive correlation between the miR-451 expression in T cells and
serum levels of IL-6 (Figure 3e), indicating that the inflammatory
status of RA patients, resulting from an active disease, may be
responsible for the observed increased expression of miR-451.
Naive and memory Treg subsets are characterized by distinct
miRNA signatures
Unsupervised clustering separated both Treg and Tconv samples
into either a naive or a memory phenotype, which was irrespective
of disease characteristics or the type of treatment (Figure 2). To
determine which miRNAs in particular were responsible for this
clustering pattern, we performed statistical analysis between the
four T-cell subsets across all eight donors. This resulted in the
identification of 42 significantly differently expressed human
miRNAs (Table 2, fold difference X2, corrected P-value o0.005).
Two-way unsupervised hierarchical clustering revealed four
distinct miRNA clusters (I–IV) separating the samples into four
cellular phenotypes (Figure 4a, and Table 2). MiRNAs defined in
cluster I were overrepresented in naive Tconvs and under-
represented in memory Tregs. MiRNAs defined in cluster II were
overrepresented in naive T cells irrespective of CD25 expression.
MiRNAs defined in cluster III were overrepresented in Tregs
irrespective of naive or memory phenotype. MiRNAs defined in
cluster IV were overrepresented in memory T cells irrespective of
CD25 expression (Figure 4a). To validate these findings, we
selected nine miRNAs, two to three from each cluster, based on
their high expression and/or high-fold difference between T-cell
subsets, and based on the literature reporting involvement of a
given miRNA in the T-cell biology23,33–35 (Table 2, in bold), and we
assessed their expression in a new group of 14 donors (Table 1,
qRT–PCR validation). Expression patterns of miR-29c, miR-363,
miR-31, miR-92a, miR-146a, miR-1246, miR-21 and miR-24 were
consistent with the array data (Figure 4b), whereas the expression
of miR-320d could not be determined owing to the lack of
specificity of the primers/probe pair.
To better visualize the overlap between miRNA signatures
defining each of the four T-cell subsets, we made a Venn diagram
based on high expression levels of the significantly differentially
expressed miRNAs in each of the subsets, as defined by the
percentages given in Table 2 (Figure 5). In the Tconv subset, 16
miRNAs showed a consistent high expression in both naive and
memory phenotypes, of which 9 were also high in naive Tregs and
4 were also high in memory Tregs. Three miRNAs were highly
expressed specifically in the memory Tconvs and six miRNAs were
highly expressed specifically in naive Tconvs. In the Treg subset,
Figure 1. Purification of naive and memory Tconv and Treg populations. (a) Representative fluorescence-activated cell sorting (FACS) dot plot
depicting the gating strategy for purification of CD4þ , naive and memory Treg and Tconv subsets, based on the expression levels of CD45RO
and CD25: I naive Tregs (CD45ROCD25þþ ), II memory Tregs (CD45ROþCD25þþþ ), III memory Tconvs (CD45ROþCD25 ) and IV naive
Tconvs (CD45ROCD25 ). (b) Representative histogram depicting FACS analysis of Foxp3 protein expression in four CD4þ T-cell subsets.
(c) Naive Tregs, memory Tregs, memory Tconvs and naive Tconvs were FACS purified from peripheral blood mononuclear cell (PBMC) of
healthy donors, and Fosxp3 transcript levels were analyzed by qRT-PCR. Relative expression, normalized to the average of TATA box binding
protein and RPII reference genes is shown. Lines indicate median expression values. Each dot represents a separate donor (n¼ 4). Statistical
analysis: repeated measures analysis of variance test with Bonferroni’s multiple comparison post-test. ***Po0.0001.
miRNA in Tregs of RA patients
K Smigielska-Czepiel et al
117
& 2014 Macmillan Publishers Limited Genes and Immunity (2014) 115 – 125
five miRNAs, that is, miR-146a, miR-3162, miR-1202, miR-1246 and
miR-4281, showed a consistent high expression irrespective of the
naive or memory phenotype. Nine memory Treg-specific miRNAs
were also highly expressed in the memory Tconvs, and therefore
should be regarded as miRNAs that define a general memory
phenotype. Similarly, the three naive Treg-specific miRNAs were
Figure 2. Unsupervised hierarchical clustering of globally expressed miRNAs. (a) MiRNA expression signatures characterizing Tconvs and Tregs
were assessed in 32 samples derived from six RA patients and two HC (Table 1, array) using miRNA microarray. A heatmap of the 121 human
miRNAs detected in at least 50% of samples, ranked according to their expression in naive Tconvs is shown. Top legend (red to blue) depicts
range of log expression values. Gray coloring indicates expression below the detection limit. Similarities between samples were assessed by
one-way unsupervised hierarchical clustering (Pearson’s correlation, complete linkage) using the Genesis software. (b) Enlargement of
the hierarchical tree from a. Color coding corresponds to the four T-cell phenotypes. HC, healthy control; RA new, RA patients before the start
of treatment with disease modifying anti-rheumatic drugs; RA MTX, RA patients treated for 3 months with MTX alone; RA MTX anti-TNF-a,
RA patients treated with MTX and anti-TNFa monoclonal antibody; N, naive; M, memory.
miRNA in Tregs of RA patients
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also highly expressed in the naive Tconvs, and as such should be
regarded as miRNAs defining a general naive phenotype. Thus, the
differential expression of miRNAs between naive and memory
Treg subsets is partly a consequence of their respective naive and
memory phenotypes. Together, these data show that some
miRNAs show an abundant expression confined to Tregs
irrespective of their maturation stage (for example, miR-146a
and miR-1246), whereas several miRNAs previously linked to the
Treg phenotype (for example, miR-21 and miR-155) are in fact
specific for a memory phenotype.
DISCUSSION
Many studies, mostly in experimental models, have shown the
critical involvement of miRNAs in the maintenance of Tregs
lineage.21,24 Recently, Miyara et al.29 fueled the notion of further
complexity in the Treg compartment and underlined the necessity
to consider naive and memory Tregs as separate regulatory
entities. In this study, we performed a comprehensive analysis of
the miRNA expression profiles of naive Tregs, memory Tregs, naive
Tconvs and memory Tconvs in RA patients and HC. We found
characteristic, disease- and treatment-independent, global
miRNA expression signatures allowing a clear, miRNA-based
subclassification of T-cell subsets into naive Tconv, naive Treg
and memory-like phenotypes. In addition, we found that the
expression of miR-451 in T cells is associated with DAS28, ESR and
serum levels of IL-6.
Several reports have shown the critical involvement of miRNAs
in the maintenance of Treg lineage stability and function. The
work of Liston et al.,21 Zhou et al.24 and Cobb et al.36 clearly
demonstrates that disturbed expression of miRNAs leads to
serious and complex alterations in Treg function, resulting in the
development of systemic autoimmune-like conditions in mice.
MiRNA expression signatures characterizing Tregs of both mice
and man have been described.33,36–38 However, the gating
strategies employed so far, based on the CD25high expression,
did not include a memory marker and as such did not separate
naive and memory Treg populations. In this study we used a
recently described gating strategy,29 and we show that human
naive and memory Tregs are characterized by distinct miRNA
expression signatures. Our data clearly show that several miRNAs
previously linked to the Treg phenotype (that is, miR-21, miR-22,
miR-24 and miR-155)23,33,38 are differentially expressed between
naive and memory Tregs, and are specifically confined to a
memory T-cell phenotype. Especially intriguing, in this respect, is
the role of miR-155, which has been shown to provide a
‘competitive fitness’ to Tregs in mice.22 Differential expression of
miR-155 between naive and memory Tregs has recently been
reported in a study by Seddiki et al.,39 which is consistent with our
data. Importantly, we found that five miRNAs (miR-146a, miR-3162,
Figure 3. Expression of miR-451 correlates with DAS28. (a) MiR-451 expression was assessed in Tconvs and Tregs, of six RA patients receiving
different treatments, and two HC by miRNA microarray (Table 1, array). MiR-451 levels are higher in all T-cell subsets of patients treated with
MTX. The horizontal lines indicate the median values. Statistical analysis: analysis of variance test with the Benjamini–Hochberg correction for
multiple testing. (b) MiR-451 expression was assessed in Tconvs and Tregs in a new cohort of ten RA patients receiving different treatment and
four HC by qRT-PCR (Table 1, qRT–PCR validation). Expression was normalized to the average of RNU44 and RNU48 reference genes and to a
calibrator sample (RA-29 naive Tconv), which was set to 1. The horizontal lines indicate the median values. Statistical analysis: the Kruskal–
Wallis test with Dunn’s multiple comparison post-test. HC, healthy control; RA new, RA patients before the start of treatment with disease
modifying anti-rheumatic drugs; RA MTX, RA patients treated for 3 months with MTX alone; RA MTX anti-TNFa, RA patients treated with MTX
and anti-TNFa monoclonal antibody. (c–e) MiR-451 expression was assessed in naive Tconvs of 27 RA patients (Table 1, all patients) by
qRT–PCR. Expression was normalized to the average of RNU44 and RNU48 reference genes and a calibrator sample (RA-29 naive Tconv), which
was set to 1. Each dot represents one RA patient. (c) MiR-451 expression correlates positively with DAS28 in RA patients. (d) MiR-451
expression correlates positively with the erythrocytes sedimentation rate (ESR) in RA patients. (e) MiR-451 expression correlates positively with
IL-6 levels detected in the serum of RA patients. *Po0.05, **Po0.01, ***Po0.0001.
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Table 2. MiRNAs with significant differential expression levels between T-cell subsets
Cluster I: naive Tconv
Geomean expression array data Min–max Change vs naive Tconv (%)
miRNA naive Tconv Memory Tconv Memory Treg Naive Treg Naive Tconv
miR-7g 66 54–78 87% 46% 78% 100%
miR-29c 32 28–38 65% 27% 61% 100%
miR-342-3p 26 24–27 72% 45% 78% 100%
miR-26a 18 13–21 64% 24% 66% 100%
miR-142-5p 17 14–22 95% 49% 46% 100%
miR-146b-5p 13 10–19 59% 36% 50% 100%
miR-30b 7.3 6.0–7.9 70% 28% 72% 100%
let-7b 6.9 6.2–7.7 112% 50% 81% 100%
miR-363 2.4 1.5–4.3 20% 0.3% 23% 100%
let-7c 1.3 1.1–1.8 94% 43% 61% 100%
miR-31 1.1 0.8–1.5 44% 0.3% 26% 100%
miR-151-5p 1.0 0.8–1.3 31% 2% 37% 100%
miR-590-5p 1.0 0.8–1.2 79% 39% 48% 100%
miR-423-5p 0.3 0.2–0.4 89% 17% 82% 100%
Cluster II: naive
Geomean expression array data Min–max Change vs naive Treg (%)
miRNA Naive Treg Memory Tconv Memory Treg Naive Treg Naive Tconv
miR-92a 4.7 3.5–5.7 63% 46% 100% 87%
miR-342-5p 2.2 1.9–2.7 79% 50% 100% 107%
miR-320d 2.1 1.7–2.3 65% 48% 100% 81%
miR-320e 1.4 1.1–1.7 70% 42% 100% 87%
miR-4299 1.4 1.0–1.4 66% 40% 100% 74%
miR-320c 1.3 1.0–2.0 71% 44% 100% 91%
miR-1275 0.6 0.3–0.8 72% 16% 100% 86%
Cluster III: Treg
Geomean expression array data Min–max Change vs naive Treg (%)
miRNA Naive Treg Memory Tconv Memory Treg Naive Treg Naive Tconv
miR-146a 20 9–34 35% 100% 91% 5%
miR-3162 2.1 0.6–4.2 50% 100% 88% 37%
miR-1202 1.9 0.4–5.9 32% 100% 97% 23%
miR-1246 0.9 0.1–3.1 9% 100% 135% 6%
miR-4281 0.8 0.2–1.7 68% 100% 107% 40%
Cluster IV: memory
Geomean expression array data Min–max Change vs naive Treg (%)
miRNA Naive Tconv Memory Tconv Memory Treg Naive Treg Naive Tconv
miR-21 104 73–150 100% 179% 33% 29%
miR-16 44 32–58 100% 118% 48% 55%
miR-15b 10 6–14 100% 130% 45% 63%
miR-15a 6.7 4.0–9.2 100% 103% 35% 43%
miR-23a 5.0 4.0–6.2 100% 63% 44% 53%
miR-24 4.9 4.0–6.8 100% 81% 38% 39%
miR-27a 4.1 3.2–5.5 100% 61% 30% 50%
miR-22 2.7 1.2–3.2 100% 86% 15% 22%
miR-155 2.2 1.9–4.4 100% 157% 53% 29%
miR-425 0.7 0.6–0.9 100% 95% 49% 74%
miR-4306 0.6 0.5–0.7 100% 103% 30% 71%
miR-148a 0.5 0.4–0.7 100% 87% 26% 109%
miR-222 0.5 0.2–0.4 100% 43% 4% 34%
miR-625 0.4 0.3–0.6 100% 73% 29% 82%
miR-7 0.3 0.3–0.5 100% 112% 37% 65%
miR-454 0.2 0.1–0.3 100% 166% 3% 47%
Abbreviations: miRNA, microRNA; Tconv, conventional T cell; Tregs, regulatory T cell. Bold values indicate Po0.05.
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miR-1202, miR-1246 and miR-4281) were significantly enriched in
both naive and memory Tregs, indicating their involvement in the
maintenance of a specific Treg phenotype, whereas three miRNAs
were significantly under-represented in both Treg subsets (miR-
142-5p, let-7c and miR-590-5p). Of the miRNAs enriched in Tregs,
miR-146a stands out because of its abundant expression level.
MiR-146a is known for its involvement in innate immunity where it
has been shown to inhibit myeloid cell proliferation and
oncogenesis.40,41 In adaptive immunity, miR-146a has been
reported to control TCR signaling via negative regulation of
NF-kB42 as well as to impair IL-2 production and to protect T cells
from antigen-induced cell death.43 Interestingly, miR-146a is
induced upon T-cell activation and its elevated expression has
been previously linked to the memory T-cell phenotype.43 Indeed,
we found increased miR-146a levels in memory Tconvs compared
with naive Tconvs. Notably, miR-146a expression has been studied
Figure 4. MiRNA signatures characterizing T-cell subsets. (a) Heatmap (Pearson’s correlation, median centering miRNAs, complete linkage)
showing the miRNA expression signatures that characterize Tconvs and Tregs in 32 samples derived from six RA patients and two healthy
controls, using miRNA microarray. Statistical analysis of 121 detected miRNAs revealed 42 miRNAs significantly differently expressed between
T-cell subsets of eight donors (n¼ 32 samples, Friedman’s test, Po0.005, fold differenceX2 in at least one of six comparisons). Top legend (red
to blue) depicts range of expression values (log values). Each T-cell subset is characterized by specific miRNA signature. (b) Eight miRNAs,
differentially expressed between the four clusters as identified in a, were selected for qRT–PCR validation in a new cohort of donors (n¼ 14,
Table 1, qRT–PCR validation). Relative expression, normalized to the average of RNU44 and RNU48 reference genes is shown. Data are
depicted as median values with interquartile range. Statistical analysis: Friedman’s test with Dunn’s multiple comparison post-test. *Po0.05,
**Po0.01, ***Po0.0001.
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extensively in the context of Treg cell function in mice. It was
shown that miR-146a positively regulates the suppressive capacity
of Tregs by targeting STAT1, a transcription factor involved in the
interferon-g signaling.23 Importantly, no differential expression of
miR-146a was noted in our study between patients and controls,
or in RA patients between different arms of treatment (MTX and
MTXþ anti-TNF-a), suggesting no overt, miR-146a-mediated
deregulation of Treg function in RA. In a recent study, Rossi
et al.38 described the miRNA signature of 17 defined lymphocyte
subsets and focused on naive T-cells. In our analysis, in which we
used a slightly different sorting strategy to purify naive CD4þ
T cells, we could confirm the naive Tconv-specific expression of
miR-146b-5p and miR-26a. The pattern of miR-125b expression
in our data was also consistent with the one described by
Rossi et al.,38 that is, relatively high levels in naive Tconvs and
virtually absent in memory T cells. However, because of the very
low absolute expression level, even in the naive Tconvs, miR-125b
did not pass the filtering criteria and was not included in our
analysis.
Memory Tregs are composed of natural Tregs, which arise in the
thymus, and inducible Tregs, which arise in the periphery in
response to antigen exposure.44 The recently described possibility
to separate natural Tregs and inducible Tregs based on their
differential expression of neutropilin-145 could be used in future
studies to determine whether natural Tregs and inducible Tregs
share a common miRNA expression signature.
Our profiling did not reveal global RA-specific changes in the
miRNA signatures of the four T-cell subsets. However, we found a
positive correlation between the expression of miR-451 and
DAS28, and more specifically ESR. Furthermore, elevated miR-451
expression correlated with increased serum levels of IL-6 in RA
patients with active disease. A negative feedback loop between
IL-6 and miR-451 has been described in dendritic cells. IL-6 was
shown to induce miR-451, which in turn led to a decreased
expression of pro-inflammatory cytokines, such as IL-6, by direct
repression of the YWHAZ adapter protein.32 Further studies are
warranted to determine whether this proposed relationship
between IL-6 and miR-451 exists in T cells.
Our study clearly shows that defined T-cell subsets are
characterized by specific miRNA expression signatures. As such,
subtle changes in the CD4þ T-cell composition (for example, the
ratio of naive to memory T cells) between HC and RA patients may
readily influence the outcome of the analysis, especially for
miRNAs that show significantly different expression between the
naive and memory subsets (for example, miR-21, miR-155 or
miR-146a). Recently, Li et al.14 reported increased miR-146a levels
in T cells from synovial fluid of RA patients, as well as in T cells
treated with TNF-a. In our analysis of naive and memory T cells
isolated from peripheral blood, expression of miR-146a did not
differ between HC and RA patients. Consistently, we did not detect
increased TNF-a level in the sera of RA patients (data not shown).
The synovial fluid T-cell compartment is almost entirely composed
of memory T cells46 that are characterized by higher levels of
miR-146a than naive T cells (this study and Curtale et al.43).
Moreover, it has been shown that T-cell activation, which takes
place in the synovial fluid, significantly induces miR-146a
expression.43 Thus, a shift in the composition of synovial fluid
T cells together with an ongoing inflammatory state of the joint
might be responsible for the relatively high expression of miR-
146a observed in synovial fluid T cells. Fulci et al.47 have recently
reported increased levels of miR-223 in peripheral blood CD4þ
T cells of RA patients. We did not observe such increase in our
analysis. This discrepancy could be a result of an interdonor
variation.
Figure 5. Venn diagram depicting subset specificity of miRNAs. MiRNAs specific for each T-cell subset were selected based on an expression
level of X70% as depicted in Table 2.
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Overall, our study provides important insight into the expres-
sion of specific miRNAs in defined T-cell subsets, especially in
naive and memory Tregs. Furthermore, our data underline the
necessity to analyze isolated T-cell populations in the search for
disease-specific molecular cues such as miRNAs.
MATERIALS AND METHODS
Patient’s characteristics
Peripheral blood was obtained from 27 RA patients and 6 HC. All RA
patients fulfilled the 1987 ACR criteria for the classification of RA. Twenty-
four patients had active disease as defined by the EULAR criteria for
active disease (DAS28 score 42.6). For 26 patients, the DAS28 score was
calculated at the time of recruitment (for 1 patient, DAS3 score was
calculated). IgM rheumatoid factor and anti-cyclic citrullinated peptide
antibodies were routinely tested, respectively, by turbidimetrics (Roche,
Mannheim, Germany) and fluorescent enzyme immune assay (Phadia,
Thermo Fisher Scientific, Uppsala, Sweden). Clinical characteristics of
patients, including medication are summarized in Table 1. None of the
patients received steroid treatment. The study was approved by the UMCG
institutional medical ethical committee (2009.118) in accordance with the
standards laid down in the 1964 Declaration of Helsinki.
Isolation of Treg and Tconv cells
Peripheral blood mononuclear cells from RA patients and HC were isolated
by density gradient centrifugation using Lymphoprep (Axis-Shield,
Oslo, Norway) immediately after blood withdrawal into heparin-
supplemented vacutainer tubes (Becton-Dickinson Biosciences, Franklin
Lakes, NJ, USA). CD3þCD8CD45ROCD25 , CD3þCD8CD45RO
CD25þþ , CD3þCD8CD45ROþCD25 and CD3þCD8CD45ROþ
CD25þþþ T cells were isolated from peripheral blood mononuclear cells
by fluorescence-activated cell sorting (MoFlo, Beckman Coulter, Brea, CA,
USA) using anti-human-CD3 (OKT3, eBioscience, San Diego, CA, USA), anti-
human-CD8 (MCD8, IQ Products, Groningen, The Netherlands) anti-human-
CD45RO (UCHL1, eBioscience) and anti-human-CD25 (2A3, Becton-Dickinson
Biosciences). Cells were immediately lysed with Qiazol reagent (Qiagen,
Venlo, The Netherlands).
Intracellular Foxp3 staining
Peripheral blood mononuclear cells were fixed, permeabilized and washed
using the Foxp3-staining Buffer Set (eBioscience). Cells were stained with
anti-human-CD3 (OKT3, eBioscience), anti-human-CD8 (MCD8, IQ Products)
anti-human-CD45RO (UCHL1, eBioscience), anti-human-CD25 (2A3, Becton-
Dickinson Biosciences) and anti-human-Foxp3 (clone 206D, BioLegend,
San Diego, CA, USA) monoclonal antibodies. Flow cytometry analysis
was performed using an LSR-II Flow Cytometer and FACSDiva software
(Becton-Dickinson Biosciences). Data were analyzed using Kaluza software
(version 1.2, Beckman Coulter).
RNA isolation
Total cellular RNA was extracted using the miRNeasy Mini Kit (Qiagen),
following the manufacturer’s instructions, with an additional chloroform
extraction step and a triple washing step. RNA concentrations were
quantified using a NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA), and RNA quality was assessed using
the Experion HighSens RNA analysis Kit (Bio-Rad, Hercules, CA, USA). RNA
samples with an RNA quality indicator value above 8.8 were used for
downstream applications.
Microarray analysis and statistics
Approximately 100 ng of total RNA was dephosphorylated, desalted and
labeled with Cy-3 and hybridized to the Agilent Human miRNA Microarray
(catelog number G4870A), which contained probes for 1205 human and
144 human viral miRNAs. Arrays were scanned using an Agilent scanner
according to the manufacturer’s instructions (Agilent Technologies). Array
images were analyzed using Agilent feature extraction software (v10.7.3.1).
All further analyses were performed using GeneSpring GX version 12.5
software (Agilent Technologies). TXT files for each array were preprocessed
using default settings as follows: threshold raw signals to 1.0, followed by
95 percentile shift normalization. We excluded control probes, miRNAs
detected in less than 50% of samples (16 out of 32 samples), and miRNAs
with an expression value below  3.5 in more than 25% of samples (8 out
of 32 samples), leaving 121 human miRNAs and 4 human viral miRNAs.
Hierarchical clustering was performed using Genesis software (Graz
University of Technology) and Pearson’s correlation as the distance metric.
Differential expression analysis between four treatment groups, irrespec-
tive of T-cell subset, was performed using an analysis of variance test with
the Benjamini–Hochberg correction for multiple testing. Probes with
corrected P-value o0.05 and fold difference X2 in at least one of the
comparisons between the groups were considered for further analysis.
Differential expression analysis across all subjects (n¼ 8) was performed
using a Friedman test between four T-cell subsets, with the Benjamini–
Hochberg correction for multiple testing. Probes with corrected
P-value o0.005 and a fold difference X2 in at least one of the
comparisons between the subsets were considered for further analysis.
Venn diagrams were constructed using an online tool http://www.bioin-
fogp.cnb.csic.es/tools/venny/.
Microarray data
The microarray data have been deposited into Gene Expression Omnibus
and are accessible with the following series record number: GSE50646.
qRT–PCR
Gene expression levels were analyzed by qRT–PCR. For miRNA-specific
complementary DNA synthesis, RNA was reverse transcribed using the
Taqman MicroRNA Reverse Transcription kit in combination with multi-
plexed reverse transcription primers of TaqMan microRNA Assays (Life
Technologies, Carlsbad, CA, USA) for miR-363-3p (ID: 001271), miR-31-5p
(ID: 002279), miR-29c-3p (ID: 000587), miR-92a-3p (ID: 000431), miR-320d
(ID: 241066_mat), miR-146a-5p (ID: 000468), miR-1246 (ID: 462575_mat),
miR-21-5p (ID: 000397), miR-24-3p (ID: 000402), miR-451a (ID: 001141),
RNU44 (ID: 001094) and RNU48 (ID: 0010060). Complementary DNA
synthesis for mRNA was performed using Superscript III RTase (Life
Technologies).
The qPCR reaction was performed using qPCR MasterMix Plus
(Eurogentec, Liege, Belgium) and Taqman Gene expression assays
for miRNAs and for Foxp3 (ID: Hs 01085834_m1) (Life Technologies).
Gene-specific primers and probe (Integrated DNA Technologies,
Coralville, IA, USA) were used for detection of TATA box binding protein:
forward 50-GCCCGAAACGCCGAATAT-30 , reverse 50-CCGTGGTTCGTGGCT
CTCT-30 and probe 50-6-FAM-ATCCCAAGCGGTTTGCTGCGG-BHQ-1-30 ; and
for the detection of RPII: forward 50-CGTACGCACCACGTCCAAT-30 , reverse
50-CAAGAGAGCCAAGTGTCGGTAA-30 , and probe 50-6-FAM-TACCACGTCA
TCTCCTTTGATGGCTCCTAT-BHQ-1-30 .
All reactions were run in triplicate. Mean cycle threshold (Ct) values for
all genes were quantified with the Sequence Detection software (version
2.3, Life Technologies) using ABI7900HT thermo cycler (Life Technologies).
RNU48 and RNU44 served as endogenous controls for the selected
miRNAs, whereas TATA box binding protein and RPII served as
endogenous controls for Foxp3, resulting in DCt values. Relative expression
levels were determined using the 2DCt formula. For the detection of miR-
451 (Figures 3b–e), relative expression levels were calculated with the
2DDCt formula, where RA-29-naive Tconv sample served as a calibrator.
Quantification of circulating cytokines
Peripheral blood was collected in anticoagulant-free tubes and incubated
to coagulation for 1 h at RT. Serum was collected by centrifugation (1400 g
for 10min) and stored at  80 1C. Sera samples were thawed to quantify
levels of cytokines using Human Th1/Th2 Essential 6-plex (Affymetrix,
eBioscience) according to the manufacturer’s instruction. Data analyses
were performed using StarStation software (Applied Cytometry, Birming-
ham, UK).
Statistical analysis
Statistical analysis of qRT–PCR data was performed with the GraphPad
Prism software (La Jolla, CA, USA). Comparisons of multiple unpaired
samples were performed using the Kruskal–Wallis test with Dunn’s
multiple comparison post-test; comparisons of more than two paired
samples were performed using the Friedman test with Dunn’s multiple
comparison post-test. Comparisons of more than two paired samples with
less than six replicates were performed using the repeated measures
analysis of variance test with Bonferroni’s multiple comparison post-test.
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For correlation comparisons, the Spearman test was used. All statistical
analyses were two sided, and the significance level used was Po0.05.
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